Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07869823RecruitingEarly Phase 1
Skin cancer treatment for head and neck
This trial tests a combination of an immunotherapy drug (cemiplimab) and a special kind of radiation for a type of skin cancer called cutaneous squamous cell carcinoma. It is designed for people whose cancer has come back or is hard to treat with standard surgery or radiation.
St Louis, MissouriAges 18 years+ - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06248944Recruiting
Italian registry for head and neck cancers
This registry collects information from Italian hospitals about people with head and neck cancers. By joining, you help doctors better understand the disease and improve future treatments.
CandioloAges 18 years+ - NCT06305910RecruitingPhase 1
Vaccine immunotherapy for recurrent brain tumors or newly diagnosed DIPG
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
Minneapolis, MinnesotaAges 2–25 - NCT06305832RecruitingPhase 2
Salvage radiation plus hormone therapy with or without rezvilutamide for rising PSA
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Nanjing, JiangsuAges 40 years+ - NCT06329999Recruiting
CMGV for recurrent AML and high-risk MDS
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05577091RecruitingPhase 1
CAR-T cell therapy for recurrent glioblastoma
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
Beijing, Beijing MunicipalityAges 18–70 - NCT05905315RecruitingPhase 2
Vulvar cancer treatment: chemoradiation vs chemotherapy then surgery
This Phase 2 trial compares two treatment approaches for some women with vulvar squamous cell cancer: chemoradiation first, or chemotherapy first followed by surgery. The goal is to see which strategy works better or is safer for tumors that are hard to remove without major pelvic surgery.
AmsterdamAges 18 years+ - NCT02889666RecruitingPhase 1
Chemo plus surgery for recurrent lung cancer
This Phase 1 trial tests whether giving chemotherapy along with surgery is safe and tolerable for people with recurrent non-small cell lung cancer. It may help guide future treatment for cancer that has returned, especially if it has not spread to distant sites.
Changchun, JilinAges 18–75 - NCT06355206Recruiting
Recurrent acute pancreatitis study and treatment
This trial follows the natural course of recurrent acute pancreatitis and tests how well treatments work for it.
Shanghai, Shanghai MunicipalityAges Any age - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT05646550RecruitingPhase 1
Antibody CC-1 for men with returning prostate cancer
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
TübingenAges 18 years+ - NCT06418087RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC
This trial tests a combination of a new immunotherapy drug (durvalumab) with standard chemotherapy for people with a rare, advanced form of lung cancer called LCNEC. It aims to see if this combination can shrink tumors or slow the cancer’s growth better than chemotherapy alone.
Bologna, BOAges 18 years+ - NCT06420427Recruiting
Blood test to predict cervical cancer return after surgery
This trial uses a simple blood test to look for cancer DNA (ctDNA) and HPV DNA after cervical cancer surgery. The goal is to detect any return of the cancer early, so you and your doctor can act quickly.
Guangzhou, GuangdongAges 18 years+ - NCT07850869Recruiting
Virus injection plus immunotherapy for advanced breast cancer
This study tests a new approach that combines a modified virus (H101) injected directly into the tumor with immunotherapy drugs that help your immune system fight cancer. It is for people with advanced breast cancer who have already tried standard treatments and could not continue chemotherapy.
Guangdong, FoshanAges 18–75 - NCT07848750Recruiting
Finger-press test for liver cancer detection
This study tests a new, non-invasive finger-press test that may help detect liver cancer (hepatocellular carcinoma). It compares results from people with liver cancer, people with benign liver disease, and healthy people to see if the test can tell them apart.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06084897RecruitingPhase 2
Radiotherapy for metastatic esophageal cancer responding to immunotherapy
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06464068RecruitingPhase 2
Immunotherapy plus chemo for first-line advanced extrapulmonary small cell cancer
This trial tests a new combination of durvalumab (an immunotherapy) plus standard chemotherapy for people with advanced small cell carcinoma that started outside the lung and has not been treated before. The goal is to see if this combo works better than chemo alone.
Reggio EmiliaAges 18 years+ - NCT04790305RecruitingPhase 4
Huaier granules with standard therapy for early triple-negative breast cancer
This trial looks at whether adding Huaier granules to usual after-surgery treatment can improve outcomes for people with high-risk early-stage triple-negative breast cancer. It focuses on whether the added supplement is safe and helpful after standard care.
Hefei, AnhuiAges 18–70 - NCT07824791Recruiting
Predicting return of Crohn's disease after bowel surgery
This study looks at what happens to people with Crohn's disease after they have surgery to remove a diseased part of their intestine. The goal is to find patterns or signs that might help predict whether the disease will come back, which could help doctors plan better follow-up care.
Guangzhou, GuangdongAges 18–70 - NCT07814287RecruitingPhase 2
New drug combo for advanced EGFR-positive head and neck cancer
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Guangzhou, GuangdongAges 18–70 - NCT06243393RecruitingPhase 2/Phase 3
Sacituzumab govitecan for advanced colorectal cancer
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07807241RecruitingPhase 1
Study of MX006 for advanced tumors with B7-H3
This trial tests a new drug (MX006) in people with advanced or metastatic tumors that have a specific marker called B7-H3. The drug may work by targeting this marker to stop cancer growth. The study aims to see if MX006 is safe and effective in this patient group.
Sarasota, FloridaAges 18 years+ - NCT03577197Recruiting
Breast cancer registry for advanced disease in southeast Netherlands
This trial is a cancer registry, meaning your medical information is collected and stored for people with advanced breast cancer. It can help researchers learn from real-world care patterns and outcomes across multiple hospitals in southeast Netherlands.
MaastrichtAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.